Treatment outcomes of extranodal diffuse large B-cell lymphoma
10.3760/cma.j.issn.1004-4221.2009.02.101
- VernacularTitle:99例结外弥漫性大B细胞淋巴瘤的治疗结果
- Author:
Shunan QI
;
Yexiong LI
;
Qingfeng LIU
;
Hui FANG
;
Hua WANG
;
Jing JIN
;
Weihu WANG
;
Yongwen SONG
;
Shulian WANG
;
Yueping LIU
;
Xinfan LIU
;
Zihao YU
- Publication Type:Journal Article
- Keywords:
Lymphoma,diffuse large B-cell;
Lymphoma,extranedal;
Treatment outcome
- From:
Chinese Journal of Radiation Oncology
2009;18(2):101-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical features and treatment outcomes of extranodal diffuse large B-cell lymphoma(DLBCL). Methods Ninety-nine consecutively diagnosed patients with extranodal DLBCL were reviewed. All patients were confirmed by a combination of morphologic and immunohistochemi-cal evaluation. The primary sites of extranodal DLBCL were the gastrointestine(n = 32) ,central nerve system (CNS)/testis(n=14) ,and other sites (n = 53). Results Extranodal DLBCL was characterized by a pre-dominance in old males,less frequency of B symptorns,a large proportion of stage Ⅰ-Ⅱ disease and low in-ternational prognostic factor(IP1) score. The 5-year overall survival(OS) rate for all patients was 78.9%. The corresponding OS rate was 82.5% for gastrointestinal origin, 37.0% for CNS and testis origin and 74.6% for other organ origin, respectively. On univariate analysis, performance status, IPI score and more than one extranedal site involvement were the prognostic predictors for 5-year OS. Conclusions Being a heterogeneous group of lymphomas, extranedal DLBCL has good prognosis except those derived from the CNS and testis.
